Novartis: positive results for psoriatic arthritis.
(CercleFinance.com) - Novartis' Cosentyx reduced the signs and symptoms of psoriatic arthritis (PsA), while significantly inhibiting the progression of joint structural damage, phase III data showed.
The Swiss biopharmaceutical firm today announced results from a study involving nearly 1,000 patients and showing that structural joint damage in patients taking Cosentyx was inhibited at 24 weeks, versus placebo.
The data was presented for the first time today at the 2017 American College of Rheumatology/Association of Rheumatology Health Professionals (ACR/ARHP) meeting in San Diego.
Copyright (c) 2017 CercleFinance.com. All rights reserved.
The Swiss biopharmaceutical firm today announced results from a study involving nearly 1,000 patients and showing that structural joint damage in patients taking Cosentyx was inhibited at 24 weeks, versus placebo.
The data was presented for the first time today at the 2017 American College of Rheumatology/Association of Rheumatology Health Professionals (ACR/ARHP) meeting in San Diego.
Copyright (c) 2017 CercleFinance.com. All rights reserved.